1
|
Ellenbroek BD, Kahler JP, Evers SR, Pomplun SJ. Synthetic Peptides: Promising Modalities for the Targeting of Disease-Related Nucleic Acids. Angew Chem Int Ed Engl 2024; 63:e202401704. [PMID: 38456368 DOI: 10.1002/anie.202401704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2024] [Revised: 03/06/2024] [Accepted: 03/08/2024] [Indexed: 03/09/2024]
Abstract
DNA and RNA play pivotal roles in life processes by storing and transferring genetic information, modulating gene expression, and contributing to essential cellular machinery such as ribosomes. Dysregulation and mutations in nucleic acid-related processes are implicated in numerous diseases. Despite the critical impact on health of nucleic acid mutations or dysregulation, therapeutic compounds addressing these biomolecules remain limited. Peptides have emerged as a promising class of molecules for biomedical research, offering potential solutions for challenging drug targets. This review focuses on the use of synthetic peptides to target disease-related nucleic acids. We discuss examples of peptides targeting double-stranded DNA, including the clinical candidate Omomyc, and compounds designed for regulatory G-quadruplexes. Further, we provide insights into both library-based screenings and the rational design of peptides to target regulatory human RNA scaffolds and viral RNAs, emphasizing the potential of peptides in addressing nucleic acid-related diseases.
Collapse
Affiliation(s)
| | | | - Sophie R Evers
- Leiden University, 2333 CC, Leiden, The Netherlands
- Present address, Department of Chemistry, University of Zurich, Wintherthurerstrasse 190, 8057, Zurich, Switzerland
| | | |
Collapse
|
2
|
Wynn JE, Santos WL. HIV-1 drug discovery: targeting folded RNA structures with branched peptides. Org Biomol Chem 2015; 13:5848-58. [PMID: 25958855 PMCID: PMC4511164 DOI: 10.1039/c5ob00589b] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Human immunodeficiency virus type 1 (HIV-1) is an RNA virus that is prone to high rates of mutation. While the disease is managed with current antiretroviral therapies, drugs with a new mode of action are needed. A strategy towards this goal is aimed at targeting the native three-dimensional fold of conserved RNA structures. This perspective highlights medium-sized peptides and peptidomimetics used to target two conserved RNA structures of HIV-1. In particular, branched peptides have the capacity to bind in a multivalent fashion, utilizing a large surface area to achieve the necessary affinity and selectivity toward the target RNA.
Collapse
Affiliation(s)
- Jessica E Wynn
- Department of Chemistry and Virginia Tech Center for Drug Discovery, Virginia Tech, Blacksburg, Virginia 24061, USA.
| | | |
Collapse
|
3
|
Kameyama S, Okada R, Kikuchi T, Omura T, Nakase I, Takeuchi T, Sugiura Y, Futaki S. Distribution of Immunoglobulin Fab Fragment Conjugated with HIV-1 REV Peptide following Intravenous Administration in Rats. Mol Pharm 2005; 3:174-80. [PMID: 16579646 DOI: 10.1021/mp050064m] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
HIV-1 REV peptide (positions 34-50) is well-known as a cell-permeating peptide. In this study, we investigated the distribution of Fab fragment of immunoglobulin conjugated with REV peptide (REV-Fab) following intravenous administration in rats, and compared with those of the native Fab fragment (nFab). Radioiodinated REV-Fab or nFab ((125)I-REV-Fab or (125)I-nFab, respectively) was given in a single intravenous dose of 2 mg/kg (3 MBq/kg). Total radioactive and TCA-insoluble radioactive concentrations in blood, whole-body autoradiography (ARG), and urinary excretion rates were assayed following administration. Regarding blood and plasma, total radioactive and TCA-insoluble radioactive concentrations for (125)I-REV-Fab were remarkably lower than those for (125)I-nFab. In the whole-body ARG at 4 h after administration, (125)I-REV-Fab produced remarkably higher radioactivity in the adrenal gland, spleen, and liver, compared to (125)I-nFab. Regarding urinary excretion rates, approximately 70% of the radioactive dose was excreted in the form of a low-molecular-weight component by 24 h after administration for both samples. (125)I-REV-Fab may penetrate quickly from blood to adrenal gland, spleen, liver, and other tissues after intravenous administration to rats, and then did not stay in situ and was digested and excreted mostly via the renal route by 24 h. With these features, cell-permeating peptides are expected to help the development of new antibody pharmaceuticals.
Collapse
Affiliation(s)
- Shouju Kameyama
- Research Planning, Bipha Corporation, Chitose, Hokkaido 066-0051, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Lapidot A, Vijayabaskar V, Litovchick A, Yu J, James TL. Structure-activity relationships of aminoglycoside-arginine conjugates that bind HIV-1 RNAs as determined by fluorescence and NMR spectroscopy. FEBS Lett 2004; 577:415-21. [PMID: 15556620 DOI: 10.1016/j.febslet.2004.10.038] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2004] [Revised: 10/11/2004] [Accepted: 10/14/2004] [Indexed: 11/28/2022]
Abstract
We present here a new set of aminoglycoside-arginine conjugates (AACs) that are either site-specific or per-arginine conjugates of paromomycin, neamine, and neomycin B as well as their structure-activity relationships. Their binding constants (KD) for TAR and RRE RNAs, measured by fluorescence anisotropy, revealed dependence on the number and location of arginines in the different aminoglycoside conjugates. The binding affinity of the per-arginine aminoglycosides to TAR is higher than to RRE, and hexa-arginine neomycin B is the most potent binder (KD=5 and 23 nM, respectively). The 2D TOCSY NMR spectrum of the TAR monoarginine-neomycin complex reveals binding at the bulge region of TAR.
Collapse
Affiliation(s)
- Aviva Lapidot
- Department of Organic Chemistry, Weizmann Institute of Science, Rehovot 76100, Israel.
| | | | | | | | | |
Collapse
|
5
|
Kaushik N, Pandey VN. PNA targeting the PBS and A-loop sequences of HIV-1 genome destabilizes packaged tRNA3(Lys) in the virions and inhibits HIV-1 replication. Virology 2002; 303:297-308. [PMID: 12490391 DOI: 10.1006/viro.2002.1630] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
During assembly of the HIV-1 virions, cellular tRNA(Lys)(3) is packaged into the virion particles and is utilized as a primer for the initiation of reverse transcription. The 3'-terminal 18 nucleotides of the cellular tRNA(Lys)(3) are complementary to nucleotides 183-201 of the viral RNA genome, referred to as the primer binding sequence (PBS). Additional sequences (A-Loop) upstream of the PBS are essential for tRNA primer selection. We report here that a PNA targeted to PBS and A-Loop sequence (PNA(PBS)) exhibits high specificity for its target sequence and prevents tRNA(Lys)(3) priming on the viral genome. We also demonstrate that PNA(PBS) is able to invade the duplex region of the tRNA(Lys)(3)-viral RNA complex and destabilize the priming process, thereby inhibiting the in vitro initiation of reverse transcription. The endogenously packaged tRNA(Lys)(3) bound to the PBS region of the viral RNA genome in the HIV-1 virion is efficiently competed out by PNA(PBS), resulting in near complete inhibition of initiation of endogenous reverse transcription. Examination of the effect of PNA(PBS) on HIV-1 production in CEM cells infected with pseudotyped HIV-1 virions carrying luciferase reporter exhibited dramatic reduction of HIV-1 replication by nearly 99%. Analysis of the mechanism of PNA(PBS)-mediated inhibition indicated that PNA(PBS) interferes at the step of reverse transcription. These findings suggest the antiviral efficacy of PNA(PBS) in blocking the process of HIV-1 replication.
Collapse
Affiliation(s)
- Neerja Kaushik
- Center for the Study of Emerging and Re-Emerging Pathogens, Department of Biochemistry and Molecular Biology, UMD-New Jersey Medical School, 185 South Orange Avenue, Newark, New Jersey 07103, USA.
| | | |
Collapse
|
6
|
Litovchick A, Lapidot A, Eisenstein M, Kalinkovich A, Borkow G. Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: synthesis and anti-HIV activities. Biochemistry 2001; 40:15612-23. [PMID: 11747436 DOI: 10.1021/bi0108655] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
HIV-1 transactivating protein Tat is essential for virus replication and progression of HIV disease. HIV-1 Tat stimulates transactivation by binding to HIV-1 transactivator responsive element (TAR) RNA, and while secreted extracellularly, it acts as an immunosuppressor, an activator of quiescent T-cells for productive HIV-1 infection, and by binding to CXC chemokine receptor type 4 (CXCR4) as a chemokine analogue. Here we present a novel HIV-1 Tat antagonist, a neomycin B-hexaarginine conjugate (NeoR), which inhibits Tat transactivation and antagonizes Tat extracellular activities, such as increased viral production, induction of CXCR4 expression, suppression of CD3-activated proliferation of lymphocytes, and upregulation of the CD8 receptor. Moreover, Tat inhibits binding of fluoresceine isothiocyanate (FITC)-labeled NeoR to human peripheral blood mononuclear cells (PBMC), indicating that Tat and NeoR bind to the same cellular target. This is further substantiated by the finding that NeoR competes with the binding of monoclonal Abs to CXCR4. Furthermore, NeoR suppresses HIV-1 binding to cells. Importantly, NeoR accumulates in the cell nuclei and inhibits the replication of M- and T-tropic HIV-1 laboratory isolates (EC(50) = 0.8-5.3 microM). A putative model structure for the TAR-NeoR complex, which complies with available experimental data, is presented. We conclude that NeoR is a multitarget HIV-1 inhibitor; the structure, and molecular modeling and dynamics, suggest its binding to TAR RNA. NeoR inhibits HIV-1 binding to cells, partially by blocking the CXCR4 HIV-1 coreceptor, and it antagonizes Tat functions. NeoR is therefore an attractive lead compound, capable of interfering with different stages of HIV infection and AIDS pathogenesis.
Collapse
MESH Headings
- Amino Acid Sequence
- Animals
- Anti-HIV Agents/chemical synthesis
- Anti-HIV Agents/metabolism
- Anti-HIV Agents/pharmacology
- Arginine/pharmacology
- Binding Sites/drug effects
- CD4 Antigens/metabolism
- CD8 Antigens/biosynthesis
- CD8 Antigens/metabolism
- Cells, Cultured
- Extracellular Space/drug effects
- Extracellular Space/metabolism
- Extracellular Space/virology
- Fluorescent Dyes/metabolism
- Framycetin/analogs & derivatives
- Framycetin/chemical synthesis
- Framycetin/metabolism
- Framycetin/pharmacology
- Gene Products, tat/antagonists & inhibitors
- Gene Products, tat/metabolism
- Gene Products, tat/physiology
- HIV Long Terminal Repeat/drug effects
- HIV-1/drug effects
- HIV-1/growth & development
- Humans
- Immunosuppressive Agents/antagonists & inhibitors
- Immunosuppressive Agents/pharmacology
- Lymphocyte Activation/drug effects
- Lymphocytes/drug effects
- Lymphocytes/metabolism
- Molecular Sequence Data
- Monocytes/drug effects
- Monocytes/metabolism
- RNA, Viral/metabolism
- Rats
- Receptors, CCR5/metabolism
- Receptors, CXCR4/antagonists & inhibitors
- Receptors, CXCR4/biosynthesis
- Receptors, CXCR4/metabolism
- Transcriptional Activation/drug effects
- U937 Cells
- Up-Regulation/drug effects
- tat Gene Products, Human Immunodeficiency Virus
Collapse
Affiliation(s)
- A Litovchick
- Department of Organic Chemistry, Weizmann Institute of Science, 76100 Rehovot, Israel
| | | | | | | | | |
Collapse
|
7
|
Kaushik N, Talele TT, Monel R, Palumbo P, Pandey VN. Destabilization of tRNA3(Lys) from the primer-binding site of HIV-1 genome by anti-A loop polyamide nucleotide analog. Nucleic Acids Res 2001; 29:5099-106. [PMID: 11812842 PMCID: PMC97570 DOI: 10.1093/nar/29.24.5099] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Initiation of human immunodeficiency virus type 1 (HIV-1) reverse transcription occurs by extension of the cellular tRNA3(Lys) which anneals to the primer-binding site (PBS) on the 5' non-translated region of the viral RNA genome. The A-rich sequence (A-loop) upstream of the PBS interacts with the anticodon loop of tRNA3(Lys) and has been proposed to be essential for conferring specificity to tRNA3(Lys) for priming the initiation of HIV-1 reverse transcription. We observed that polyamide nucleic acid targeted to the A-loop sequence (PNAAL) exhibits high binding specificity for its target sequence. The PNAAL pre-bound to the A-loop sequence prevents tRNA3(Lys) priming on the viral RNA consequently blocking in vitro initiation of reverse transcription. Further, PNAAL can efficiently disrupt the preformed [tRNA3(Lys)--viral RNA] complex thereby rendering it non-functional for reverse transcription. The endogenous reverse transcription in disrupted HIV-1 virions containing packaged tRNA3(Lys) and its replicating enzyme RT was significantly inhibited by PNAAL, thus providing direct evidence of the involvement of the A-loop region of viral RNA genome in tRNA3(Lys) priming process. These findings suggest the potential of the A-loop region as a critical target for blocking HIV-1 replication.
Collapse
MESH Headings
- Base Sequence
- Binding Sites
- DNA, Antisense/chemistry
- DNA, Antisense/metabolism
- DNA, Antisense/pharmacology
- Dose-Response Relationship, Drug
- Genome, Viral
- HIV-1/drug effects
- HIV-1/genetics
- HIV-1/metabolism
- Molecular Sequence Data
- Nucleic Acid Conformation
- Nylons/chemistry
- Peptide Nucleic Acids/chemistry
- Peptide Nucleic Acids/metabolism
- Peptide Nucleic Acids/pharmacology
- RNA, Transfer, Lys/chemistry
- RNA, Transfer, Lys/genetics
- RNA, Transfer, Lys/metabolism
- RNA, Viral/chemistry
- RNA, Viral/drug effects
- RNA, Viral/genetics
- Transcription, Genetic/drug effects
Collapse
Affiliation(s)
- N Kaushik
- Department of Biochemistry and Molecular Biology, Center for the Study of Emerging and Re-Emerging Pathogens UMDNJ-New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103, USA
| | | | | | | | | |
Collapse
|
8
|
Takahashi T, Hamasaki K, Ueno A, Mihara H. Construction of peptides with nucleobase amino acids: design and synthesis of the nucleobase-conjugated peptides derived from HIV-1 Rev and their binding properties to HIV-1 RRE RNA. Bioorg Med Chem 2001; 9:991-1000. [PMID: 11354682 DOI: 10.1016/s0968-0896(00)00324-2] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
In order to develop a novel molecule that recognizes a specific structure of RNA, we have attempted to design peptides having L-alpha-amino acids with a nucleobase at the side chain (nucleobase amino acid (NBA)), expecting that the function of a nucleobase which can specifically recognize a base in RNA is regulated in a peptide conformation. In this study, to demonstrate the applicability of the NBA units in the peptide to RNA recognition, we designed and synthesized a variety of NBA-conjugated peptides, derived from HIV-1 Rev. Circular dichroism study revealed that the conjugation of the Rev peptide with an NBA unit did not disturb the peptide conformation. RNA-binding affinities of the designed peptides with RRE IIB RNA were dependent on the structure of the nucleobase moieties in the peptides. The peptide having the cytosine NBA at the position of the Asn40 site in the Rev showed a higher binding ability for RRE IIB RNA, despite the diminishing the Asn40 function. Furthermore, the peptide having the guanine NBA at the position of the Arg44 site, which is the most important residue for the RNA binding in the Rev, bound to RRE IIB RNA in an ability similar to Rev34-50 with native sequence. These results demonstrate that an appropriate NBA unit in the peptide plays an important role in the RNA binding with a specific contact such as hydrogen bonding, and the interaction between the nucleobase in the peptide and the base in the RNA can enhance the RNA-binding affinity and specificity.
Collapse
Affiliation(s)
- T Takahashi
- Department of Bioengineering, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama, Japan
| | | | | | | |
Collapse
|
9
|
Kumagai I, Takahashi T, Hamasaki K, Ueno A, Mihara H. HIV Rev peptides conjugated with peptide nucleic acids and their efficient binding to RRE RNA. Bioorg Med Chem Lett 2001; 11:1169-72. [PMID: 11354369 DOI: 10.1016/s0960-894x(01)00169-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
HIV Rev peptides conjugated with peptide nucleic acids (PNAs) were designed and synthesized to develop a designing approach for a novel RNA-binding molecule. The binding affinities of PNA-peptides with the Rev responsive element (RRE) RNA were determined by the competition assay using a rhodamine-labeled Rev. The peptide conjugated with an antisense PNA (TGCGC) bound RRE RNA more efficiently than the molecule without the PNA or the peptide sequence.
Collapse
Affiliation(s)
- I Kumagai
- Department of Bioengineering, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Nagatsuta, Yokohama, Japan
| | | | | | | | | |
Collapse
|
10
|
Pooga M, Land T, Bartfai T, Langel U. PNA oligomers as tools for specific modulation of gene expression. BIOMOLECULAR ENGINEERING 2001; 17:183-92. [PMID: 11337277 DOI: 10.1016/s1389-0344(01)00075-2] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Small synthetic molecules that can specifically inhibit translation and/or transcription have shown great promise as potential antisense/antigene drugs. Peptide nucleic acid (PNA), an oligonucleotide mimic, has a non-charged achiral polyamide backbone to which the nucleobases are attached. PNA oligomers are extremely stable in biological fluids and they specifically hybridise to DNA or RNA in a complementary manner, forming very strong heteroduplexes. Some of the mRNAs have yet undetermined and possibly long half-lives, successful down regulation of gene expression by antisense oligonucleotides (ON) requires that the antisense agent is long lived. PNA fulfils this requirement better than phosphodiester or phosphorothioate ONs. PNA can inhibit transcription and translation of respective genes by tight binding to DNA or mRNA. First in vitro experiments to specifically down regulate protein expression by PNA have been followed by successful antisense and antigene application of PNA oligomers in vivo. This review discusses the principles of the in vitro and in vivo use of PNA oligonucleotides.
Collapse
Affiliation(s)
- M Pooga
- Department of Neurochemistry and Neurotoxicology, Arrhenius Laboratories, Stockholm University, S-10691 Stockholm, Sweden
| | | | | | | |
Collapse
|
11
|
Matsumoto C, Hamasaki K, Mihara H, Ueno A. A high-throughput screening utilizing intramolecular fluorescence resonance energy transfer for the discovery of the molecules that bind HIV-1 TAR RNA specifically. Bioorg Med Chem Lett 2000; 10:1857-61. [PMID: 10969985 DOI: 10.1016/s0960-894x(00)00359-0] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
A 16-residue peptide, including the Tat(49-57) sequence was labeled with a fluorescein and a tetramethylrhodamine at its N- and C-terminus, respectively. This double dye-labeled peptide was prepared as a tracer for high-throughput screening utilizing intramolecular fluorescence resonance energy transfer (FRET). The binding of the competitor molecules for HIV-1 TAR RNA were monitored and dissociation constants of those molecule were determined by using this tracer. This novel screening system might be useful to discover the drug for HIV-1 TAR RNA.
Collapse
Affiliation(s)
- C Matsumoto
- Department of Bioengineering, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Nagatsuta, Yokohama, Japan
| | | | | | | |
Collapse
|